Arunjyoti Bio Ventures Ltd

Arunjyoti Bio Ventures Ltd reported audited financial results for the quarter and year ended March 31, 2026. The company's total income for the year stood at ₹2,787.24 Lakhs, while total expenses amounted to ₹3,027.61 Lakhs, resulting in a net loss after tax of ₹453.61 Lakhs. The board also approved the write-off of outstanding Debtors and Creditors amounting to ₹273.65 Lakhs.

Arunjyoti Bio Ventures Ltd has announced the postponement of its Board Meeting, initially scheduled for May 12, 2026, to May 13, 2026. The meeting will still address the consideration and approval of Audited Financial Results, as previously indicated in earlier intimations dated May 1, 2026, and May 5, 2026. The agenda remains unchanged, and the meeting will take place at the company's registered office.

Arunjyoti Bio Ventures Ltd has rescheduled its Board Meeting to May 12, 2026, to consider and approve the Audited Financial Results. The meeting was initially scheduled for May 8, 2026, but was postponed due to unavoidable reasons. The agenda remains the same as previously intimated.

Arunjyoti Bio Ventures Ltd has scheduled a Board of Directors meeting on May 8, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The meeting will take place at the company's registered office in Telangana.

Chennupati Sarath Kumar has disclosed the sale of 5,425,516 equity shares of Arunjyoti Bio Ventures Ltd. The transaction, executed through open market operations between April 13 and April 16, 2026, reduced his shareholding from 7.57% (14,101,138 shares) to 4.66% (8,675,622 shares) of the company's total equity. This disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Arunjyoti Bio Ventures Ltd has issued a clarification regarding instances of unsolicited messages circulating about its shares. The company has been informed of these alleged messages and, in response, advises investors to exercise due care and caution when dealing in its scrip. This disclosure is made in accordance with Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Chennupati Sarath Kumar has disclosed the sale of 60,97,684 equity shares of Arunjyoti Bio Ventures Limited through open market transactions. The sales took place between March 23, 2026, and April 10, 2026. Prior to this transaction, Kumar held 2,01,98,822 shares, representing 10.84% of the company's total voting capital. Following the sale, his shareholding has reduced to 1,41,01,138 shares, which constitutes approximately 7.56% of the total diluted share capital. This disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Arunjyoti Bio Ventures Ltd has announced the closure of its trading window under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure will be in effect from 01.04.2026 till 48 hours after the declaration of Audited Financial Results for the quarter and year ending 31.03.2026. This decision applies to all designated persons, their immediate relatives, and all connected persons covered under the Company’s Code of Conduct. The Board Meeting is scheduled to consider and approve the Audited Financial Results for the quarter and year ending 31.03.2026. An intimation regarding the notice of the Board Meeting will be sent separately to the Exchange.

Arunjyoti Bio Ventures Limited has installed and commissioned a new Jelly Pouch Production Line at its manufacturing facility in Jangaon, Telangana. This new line is specifically set up to manufacture Z5/- Jelly Pouch packs for supply to Tata Consumer Products Limited, aiming to enhance production capacity and strengthen their business relationship. The commercial production from this line began on 10th March 2026.

Arunjyoti Bio Ventures Ltd has announced that its Board of Directors will meet on February 03, 2026, to consider and approve the Un-audited financial results for the quarter ended 31.12.2025. The meeting will take place at the company's registered office in Hyderabad, Telangana.